New vaccine trial aims to boost immune system against deadly brain cancer
NCT ID NCT07347210
Summary
This study is testing whether adding a new cancer vaccine called UCPVax, with or without an immunotherapy drug (pembrolizumab), can help people live longer with a specific type of aggressive brain tumor (glioblastoma). It will involve about 98 adults who have already had initial surgery and radiation. The goal is to see if this combination can better train the body's immune system to fight the cancer during standard follow-up chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU La Timone
Marseille, France
Contact
Contact
-
CHU de Besançon
Besançon, France
Contact
Contact
-
Centre Georges François Leclerc
Dijon, France
Contact
Contact
-
Hôpital Saint-Louis - APHP
Paris, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.